Table 18:
Cost–Utility Analysis: PGx Versus TAU
| Strategy | Mean Costs, $ (95% CrI) | Mean QALYs (95% CrI) | Mean Incremental Costs,a $ (95% CrI) | Incremental QALYsb Mean (95% CrI) | ICER: $/QALY Gainedc |
|---|---|---|---|---|---|
| TAU | 8,850.79 (8,493; 9,216) |
0.587 (0.421; 0.744) |
— | — | — |
| PGx | 10,757.28 (9,450; 12,231) |
0.6186 (0.468; 0.759) |
1,906.48 (688; 3,360) |
0.031 (0.005; 0.072) |
60,564 |
Abbreviations: CrI, credible interval; ICER, incremental cost-effectiveness ratio; PGx, multi-gene pharmacogenomic-guided treatment; QALY, quality-adjusted life-year; TAU, treatment as usual.
a
Incremental cost = mean cost (strategy PGx) – mean cost (strategy TAU).
b
Incremental effect = mean effect (strategy PGx) – mean effect (strategy TAU).
c
Results might appear incorrect owing to rounding.